Laddar populära aktier...
Hög försäljningstillväxt EQL Pharma ökade de återkommande intäkterna med 46,0 procent, vilket var i ...
22% organic sales growth y-o-y Lower than expected gross margin Price increases should help gross ma...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) har presenterat Bolagets Q1-rappo...
Record start to '24, driven by Capital Markets and PI We increase adj.
Redeye provides a reseach update following the Q1 2024 report from Fragbite Group.
Redeye returns with a research update following Xbrane’s Q1 report.
Rudd delivers SEK 60m EBIT in its first full quarter (ABGSCe 68m) EBIT down by 9-7% for '24e-'26e, l...
We make minor cuts to our estimates after Ferronordic's Q1 results.
Soft Q1 combined with a downgrade of the FY'24 guidance Synergies unlikely to show in '24e: cutting ...
Adj. EBIT +3% y-o-y, despite a 7% sales drop y-o-y We make small estimate revisions +16% adj.
VBG Group fortsätter leverera starka resultat. Bolaget gynnas av en stark efterfrågan inom bussegmen...
Pharma Equity Group published its Q1 report for 2024 on the 16th of May, 2024.
Omsättningen kom i linje med vår prognos men resultatet pressades av höga avskrivningar.
First Venture publicerade den 15 maj 2024 bolagets delårsrapport för det första kvartalet av 2024.
Q1 EBITDAC below on costs, reiterates FY'24 guidance Expect continued positive momentum New guidance...